Recent Updates
Recently added Catalysts

LIK066

Phase 2

Obese Patients With Non-alcoholic Steatohepatitis (NASH) | Small molecule | Infectious Disease |Novartis AG|Last Updated: Oct 8, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment107
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03205150Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsPHASE2 COMPLETED 107Oct 4, 2017Nov 14, 2019Oct 8, 202115 United States, Argentina +6
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in Alanine Aminotransferase (ALT) at Week 12
Baseline, Week 12

Alanine aminotransferase (ALT) is an enzyme found primarily in the liver. ALT is increased with liver damage. In this study, the blood levels of ALT was used to detect liver injury. Baseline is defined as the mean of measurements taken at the Screening and Baseline visits.

Secondary Endpoints
Change From Baseline in Percent Liver Fat at Week 12
Baseline, Week 12
Percent Change From Baseline in Total Body Weight at Week 12
Baseline, Week 12
Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Week 12
Baseline, Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
LIK066 30 mgEXPERIMENTALFilm coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
LIK066 150 mgEXPERIMENTALFilm coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
PlaceboEXPERIMENTALLIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
Interventions
NameTypeDescription
LIK066DRUGFilm coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
PlaceboDRUGLIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion Criteria: EITHER -Histologic confirmed NASH based on liver biopsy obtained 2 years or less before randomization with a fibrosis level of F1, F2 or F3 in the absence of a histological diagnosis of alternative chronic liver disease AND ALT greater than or equal to 50 IU/L (males) or greate...

Countries:United StatesArgentinaCanadaIsraelNetherlandsRussiaTaiwanThailand
Unlock Eligibility Criteria